ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1860

An Integrative Approach to Identify Heritable and De Novo Genomic Variations in Psoriatic Arthritis Mutilans and Understand Its Systems Biology

Sara Rahmati1, Quan Li1, Dafna Gladman2, Proton Rahman3 and Vinod Chandran2, 1University Health Network, Toronto, ON, Canada, 2Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3Memorial University of Newfoundland, Department of Medicine, St John's, Canada

Meeting: ACR Convergence 2020

Keywords: Bioinformatics, genetics, Genome Wide Association Studies, genomics, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriasis is a chronic autoimmune skin disease that burdens ~3% of North Americans. ~24% of psoriatic patients develop psoriasis arthritis (PsA), an inflammatory disease which is often progressive and in its extreme form, PsA mutilans, causes permanent joint damage and functional disability. PsA is highly heritable; ~40% of patients with PsA have at least one close relative with psoriasis or PsA. Characterizing heritable and de novo genomic variations and cellular processes behind extreme cases of PsA is a promising approach for understanding molecular mechanisms behind PsA and identifying patients at high-risk of PsA mutilans early.

Methods: We conducted Whole Exome Sequences (WES) of 7 trios with PsA mutilans trios (probands with PsA satisfying CASPAR criteria and with arthritis mutilans and their parents), using NovSeq 6000 (Illumina) at depth 100X. We developed a bioinformatics pipeline to identify genes and pathways involved in PsA mutilans with three modules: 1) characterization of genetic variants using WES of PsA mutilans trios; 2) their integration using network-based methods to highlight pathways relevant to identified variants; 3) network analysis to identify genes and pathways to cellular mechanisms involved in PsA mutilans.

We used three available algorithms for detection of genomic variations. To discover systems level dependencies among genes and proteins to perform cellular tasks we integrated these variations with physical protein interaction networks. Next, we applied a graph-mining technique to detect network modules and several novel genes involved in PsA mutilans. Finally, we performed pathway enrichment analysis and characterized several statistically significant pathways involved in PsA mutilans.

Results: We found a subnetwork of 44 proteins [Figure 1A-B] having physical interactions with protein products of the genes identified by three variation detection methods [Table 1] suggesting implication of these 44 genes in triggered pathways in PsA mutilans. Pathway enrichment analysis highlighted WNT, NOTCH, NOTCH1, Adherens, Autophagy, and Apoptosis, suggesting their disruption in PsA mutilans [Figure 1C]. These pathways have been previously studied in psoriasis, PsA, and autoimmunity supporting relevance of identified genes and pathways to PsA mutilans. NTRK1 has the highest rank in the identified subnetwork. NTRK1, its interaction with NGF, and its mutations have previously been linked to autoimmune diseases, inflammatory arthritis, and psoriasis, and some groups are working on developing novel NGF/NTRK1-targeted therapies for these diseases. EED is another highly ranked gene in our list. Mutations in EED have been reported in several cases of over-growth disorders such as Cohen-Gibson and Weaver Syndromes. Its interaction with EZH2 (present in the list- not shown in Figure 1) has been reported to be important in psoriasis. EED mediates repression of gene activity through histone modifications.

Conclusion: Detecting heritable and de novo genomic variations by WES of PsA mutilans trios and application of network analysis has identified novel genes and pathways associated with PsA mutilans.

Table 1 List of genes with variants based on different methods.

Figure 1 A. Venn diagram summarizing overlapping protein partners of genes detected through different methods (listed in Table 1). B. Protein interaction network of genes in the three lists. For details see legend. C. Results of pathways and term enrichment analysis of the 44 genes in the center of Venn diagram (ordered on the central circle in the network).


Disclosure: S. Rahmati, None; Q. Li, None; D. Gladman, AbbVie, 2, 5, Amgen, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5, Bristol-Myers Squibb, 5, Gilead, 5, Galapagos, 5, Celgene, 2, 5, Eli Lilly, 2, 5; P. Rahman, AbbVie, 5, 8, Amgen, 5, 8, Celgene, 5, 8, Eli Lilly, 5, 8, Janssen, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 5, 8, UCB, 5, 8, Abbott, 8, Centacor, 8, Merck, 8, Bristol Myers Squibb, 5, 8, Roche, 5; V. Chandran, Abbvie, 2, 5, Amgen, 2, 5, Celgene, 2, 5, Eli Lilly, 5, Eli Lilly, 3, Janssen, 8, Novartis, 5, Pfizer, 5, UCB, 5.

To cite this abstract in AMA style:

Rahmati S, Li Q, Gladman D, Rahman P, Chandran V. An Integrative Approach to Identify Heritable and De Novo Genomic Variations in Psoriatic Arthritis Mutilans and Understand Its Systems Biology [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/an-integrative-approach-to-identify-heritable-and-de-novo-genomic-variations-in-psoriatic-arthritis-mutilans-and-understand-its-systems-biology/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-integrative-approach-to-identify-heritable-and-de-novo-genomic-variations-in-psoriatic-arthritis-mutilans-and-understand-its-systems-biology/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology